Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Eupraxia's EP-104GI Demonstrates Strong Safety And Efficacy In EoE Trial, Paving Way For Higher Dose Exploration

Author: Benzinga Newsdesk | February 25, 2025 07:51am

Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase
Cohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeks
Cohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeks
Cohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to date
Cohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at 24 weeks, showing continuously improving symptom relief over that time
For tissue health (EoEHSS) and PEC there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 showing the greatest response
No serious adverse events nor any events of oral or gastrointestinal candidiasis were reported in any of the six cohorts
Cohort 7 is fully enrolled, with 12-week data expected in Q2 2025

Posted In: EPRX